The nanoString® GeoMx platform supports quantitative analysis of proteins, phospho-proteins and mRNAs from user defined cell populations across sections of FFPE tumor tissue. The Knight Cancer Institute is a designated Center of Excellence for GeoMx applications and is working closely with nanoString in the development and validation of new biomarker targets. Over 100 proteins and 1,800 mRNAs can be rapidly analyzed with this technology.


NanoString GeoMxDigital Spatial Pathology

Most approaches to multiplexed analysis of biomarkers in FFPE tissue depend on an analog readout (immunofluorescence or histochemical stain) and are limited to a few dozen targets. The GeoMx platform uses oligonucleotide-tagged antibodies and probes that provide a digital readout with a very high dynamic range. Highly focused UV light is used to release the tags from the cells of interest (tumor, immune cells, stromal cells, etc.) and these are quantitated with either the nCounter system or next-gen sequencing. Additional information can be found at: GeoMx® Digital Spatial Profiler

NanoString GeoMx Genes image

mRNA analysis: GeoMx® Cancer Transcriptome Atlas

The GeoMx® platform can serve a wide spectrum of clinical research applications. Combinations of the markers listed below can be put together to provide a customized approach for every project. Find out more by contacting

Available Protein markers

nanoString® GeoMx Assays

Sample report

Analytical Validation of Quantitative Intracellular Protein poster presented at AMP

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More